Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Receivables (2016 - 2022)

Agios Pharmaceuticals' Receivables history spans 9 years, with the latest figure at $2.2 million for Q4 2022.

  • For Q4 2022, Receivables fell 49.61% year-over-year to $2.2 million; the TTM value through Dec 2022 reached $2.2 million, down 49.61%, while the annual FY2022 figure was $2.2 million, 49.61% down from the prior year.
  • Receivables reached $2.2 million in Q4 2022 per AGIO's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $21.3 million in Q3 2020 to a low of $2.2 million in Q4 2022.
  • Average Receivables over 5 years is $10.3 million, with a median of $8.9 million recorded in 2019.
  • Peak YoY movement for Receivables: skyrocketed 271.8% in 2018, then plummeted 53.73% in 2019.
  • A 5-year view of Receivables shows it stood at $7.5 million in 2018, then soared by 39.17% to $10.5 million in 2019, then soared by 103.25% to $21.3 million in 2020, then crashed by 79.47% to $4.4 million in 2021, then tumbled by 49.61% to $2.2 million in 2022.
  • Per Business Quant, the three most recent readings for AGIO's Receivables are $2.2 million (Q4 2022), $4.4 million (Q4 2021), and $21.3 million (Q3 2020).